Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2015 Jul;35(7):656-62.
doi: 10.1002/pd.4583. Epub 2015 May 26.

Non-invasive prenatal diagnosis of achondroplasia and thanatophoric dysplasia: next-generation sequencing allows for a safer, more accurate, and comprehensive approach

Lyn S Chitty  1   2 , Sarah Mason  3 , Angela N Barrett  3 , Fiona McKay  3 , Nicholas Lench  3 , Rebecca Daley  2 , Lucy A Jenkins  3
Affiliations
Comparative Study

Non-invasive prenatal diagnosis of achondroplasia and thanatophoric dysplasia: next-generation sequencing allows for a safer, more accurate, and comprehensive approach

Lyn S Chitty et al. Prenat Diagn. 2015 Jul.

Abstract

Objective: Accurate prenatal diagnosis of genetic conditions can be challenging and usually requires invasive testing. Here, we demonstrate the potential of next-generation sequencing (NGS) for the analysis of cell-free DNA in maternal blood to transform prenatal diagnosis of monogenic disorders.

Methods: Analysis of cell-free DNA using a PCR and restriction enzyme digest (PCR-RED) was compared with a novel NGS assay in pregnancies at risk of achondroplasia and thanatophoric dysplasia.

Results: PCR-RED was performed in 72 cases and was correct in 88.6%, inconclusive in 7% with one false negative. NGS was performed in 47 cases and was accurate in 96.2% with no inconclusives. Both approaches were used in 27 cases, with NGS giving the correct result in the two cases inconclusive with PCR-RED.

Conclusion: NGS provides an accurate, flexible approach to non-invasive prenatal diagnosis of de novo and paternally inherited mutations. It is more sensitive than PCR-RED and is ideal when screening a gene with multiple potential pathogenic mutations. These findings highlight the value of NGS in the development of non-invasive prenatal diagnosis for other monogenic disorders.

PubMed Disclaimer

Figures

Figure 1
Figure 1
PCR-restriction enzyme digest results for (a) achondroplasia [fibroblast growth factor receptor 3 (FGFR3): c.1138G>A p.(Gly380Arg)/restriction enzyme BsrG1] and (b) thanatophoric dysplasia [FGFR3: c.742C>T p.(Arg248Cys)/restriction enzyme DraIII]. Upper arrows indicate wild-type (normal) allele that is strongly present in all samples. Bottom arrows indicate the mutant alleles that are faint in affected cell-free DNA (cfDNA+) and stronger mutation positive control genomic DNA (gDNA+ve). There is no mutant band present in the unaffected maternal genomic DNA (Mat gDNA). The figure shows uncropped images visualized on Shimadzu Multi-NA microchip electrophoresis system. NTC, blank, no template control
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Tabor A, Alfirevic Z. Update on procedure-related risks for prenatal diagnosis techniques. Fetal Diagn Ther. 2010;271:1–7. - PubMed
    1. Lo YM, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and serum. Lancet. 1997;350:485–7. - PubMed
    1. Chitty LS, Bianchi DW. Non-invasive prenatal testing: the paradigm is shifting rapidly. Prenat Diagn. 2013;33:511–3. - PubMed
    1. Boon EM, Faas BH. Benefits and limitations of whole genome versus targeted approaches for non-invasive prenatal testing for fetal aneuploidies. Prenat Diagn. 2013;33:563–8. - PubMed
    1. Agarwal A, Sayres LC, Cho MK, et al. Commercial landscape of non-invasive prenatal testing in the United States. Prenat Diagn. 2013;33:521–31. - PMC - PubMed

Publication types

MeSH terms